Arrowhead Research (ARWR) Ends 1Q with $77M to Focus on HBV and AAT; Piper Jaffray Reiterates Overweight

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. LVS
9. QGEN
10. SPCX

Go back to Arrowhead Research (ARWR) Ends 1Q with $77M to Focus on HBV and AAT; Piper Jaffray Reiterates Overweight

After-Hours Stock Movers 02/09: (LLNW) (EDE) (MKTO) Higher; (MSTX) (SCTY) (P) Lower (more...)

February 9, 2016 6:12 PM EST

Mast Therapeutics, Inc. (NYSE: MSTX) 37% LOWER; announced that it intends to offer shares of common stock and warrants to purchase common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

SolarCity (Nasdaq: SCTY) 32.4% LOWER; reported Q4 EPS of ($2.37), $0.22 better than the analyst estimate of ($2.59). Revenue was $115 million, versus... More

Arrowhead Research (ARWR) Tops Q2 EPS by 9c

February 9, 2016 4:47 PM EST

Arrowhead Research (NASDAQ: ARWR) reported Q2 EPS of ($0.32), $0.09 better than the analyst estimate of ($0.41).

For earnings history and earnings-related data on Arrowhead Research (ARWR) click here.

... More